FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2247263719> ?p ?o ?g. }

• W2247263719 endingPage "2532" @default.
• W2247263719 startingPage "2532" @default.
• W2247263719 abstract "2532 Background: Pertuzumab, a humanized HER2-targeted antibody, represents the first in a new class of targeted therapeutic agents known as HER2 dimerization inhibitors (HDIs). Pertuzumab blocks ligand-associated HER2 dimerization with HER kinase family members (EGFR, HER3, HER4), thereby inhibiting intracellular signaling through MAP and PI3 kinases. Pertuzumab is currently being evaluated in phase II studies as a single-agent in ovarian, breast, prostate, and lung cancers. Interim pertuzumab PK data from the phase II studies is presented. Methods: Pertuzumab was administered once every 3 weeks (q3 week) as an IV infusion at a fixed dose of either 420 mg following an initial 840 mg loading dose (LD), or 1050 mg with no LD. PK data from four phase II studies were pooled for analysis by both descriptive and population PK (PopPK) modeling Methods: Results: PopPK modeling of the data from ovarian and breast cancer studies showed that a linear 2-compartment model best described the concentration-time profiles. For a ‘typical’ patient, pertuzumab clearance (CL), volume of distribution (Vc), and terminal half-life was 0.214 L/day, 2.74 L, and 17.2 days, respectively. Body weight (BW), serum albumin, and alkaline phosphatase were significant covariates affecting CL, with BW explaining only 8.3% of inter-patient variability for CL. Body surface area was the significant covariate affecting Vc. The q3 week 420 mg (840 mg LD) regimen attained mean serum trough concentrations of ≈50 μg/mL and steady-state concentrations were achieved by the 2nd treatment cycle in all studies. Conclusions: Pertuzumab PK supports a q3 week dosing regimen. At a fixed-dose of 420 mg (840 mg LD) steady-state was rapidly attained, and putative target trough concentrations of ≥20 μg/mL, based on in vivo xenograft tumor model data, were achieved in most patients. The PK of pertuzumab was similar to trastuzumab and bevacizumab. PopPK analysis supports the continued use of a fixed dose in women with ovarian and breast cancers. PopPK analysis for the patients in the prostate and lung cancer studies is ongoing and will be presented. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Hoffmann-La Roche Ltd., Genentech Genentech" @default.
• W2247263719 created "2016-06-24" @default.
• W2247263719 creator A5000728724 @default.
• W2247263719 creator A5016534742 @default.
• W2247263719 creator A5049851359 @default.
• W2247263719 creator A5053323627 @default.
• W2247263719 creator A5072687737 @default.
• W2247263719 creator A5082119743 @default.
• W2247263719 date "2005-06-01" @default.
• W2247263719 modified "2023-09-27" @default.
• W2247263719 title "Pharmacokinetics (PK) of pertuzumab (rhuMAb 2C4) in phase II studies of ovarian, breast, prostate, and lung cancers" @default.
• W2247263719 doi "https://doi.org/10.1200/jco.2005.23.16_suppl.2532" @default.
• W2247263719 hasPublicationYear "2005" @default.
• W2247263719 type Work @default.
• W2247263719 sameAs 2247263719 @default.
• W2247263719 citedByCount "6" @default.
• W2247263719 countsByYear W22472637192013 @default.
• W2247263719 crossrefType "journal-article" @default.
• W2247263719 hasAuthorship W2247263719A5000728724 @default.
• W2247263719 hasAuthorship W2247263719A5016534742 @default.
• W2247263719 hasAuthorship W2247263719A5049851359 @default.
• W2247263719 hasAuthorship W2247263719A5053323627 @default.
• W2247263719 hasAuthorship W2247263719A5072687737 @default.
• W2247263719 hasAuthorship W2247263719A5082119743 @default.
• W2247263719 hasConcept C112705442 @default.
• W2247263719 hasConcept C121608353 @default.
• W2247263719 hasConcept C126322002 @default.
• W2247263719 hasConcept C143998085 @default.
• W2247263719 hasConcept C2776235491 @default.
• W2247263719 hasConcept C2779786085 @default.
• W2247263719 hasConcept C2780192828 @default.
• W2247263719 hasConcept C2781164504 @default.
• W2247263719 hasConcept C2908647359 @default.
• W2247263719 hasConcept C530470458 @default.
• W2247263719 hasConcept C71924100 @default.
• W2247263719 hasConcept C98274493 @default.
• W2247263719 hasConcept C99454951 @default.
• W2247263719 hasConceptScore W2247263719C112705442 @default.
• W2247263719 hasConceptScore W2247263719C121608353 @default.
• W2247263719 hasConceptScore W2247263719C126322002 @default.
• W2247263719 hasConceptScore W2247263719C143998085 @default.
• W2247263719 hasConceptScore W2247263719C2776235491 @default.
• W2247263719 hasConceptScore W2247263719C2779786085 @default.
• W2247263719 hasConceptScore W2247263719C2780192828 @default.
• W2247263719 hasConceptScore W2247263719C2781164504 @default.
• W2247263719 hasConceptScore W2247263719C2908647359 @default.
• W2247263719 hasConceptScore W2247263719C530470458 @default.
• W2247263719 hasConceptScore W2247263719C71924100 @default.
• W2247263719 hasConceptScore W2247263719C98274493 @default.
• W2247263719 hasConceptScore W2247263719C99454951 @default.
• W2247263719 hasIssue "16_suppl" @default.
• W2247263719 hasLocation W22472637191 @default.
• W2247263719 hasOpenAccess W2247263719 @default.
• W2247263719 hasPrimaryLocation W22472637191 @default.
• W2247263719 hasRelatedWork W1499958231 @default.
• W2247263719 hasRelatedWork W1966504330 @default.
• W2247263719 hasRelatedWork W1979139803 @default.
• W2247263719 hasRelatedWork W2030889776 @default.
• W2247263719 hasRelatedWork W2037631372 @default.
• W2247263719 hasRelatedWork W2040058909 @default.
• W2247263719 hasRelatedWork W2051784208 @default.
• W2247263719 hasRelatedWork W2064362993 @default.
• W2247263719 hasRelatedWork W2132898409 @default.
• W2247263719 hasRelatedWork W2899084033 @default.
• W2247263719 hasVolume "23" @default.
• W2247263719 isParatext "false" @default.
• W2247263719 isRetracted "false" @default.
• W2247263719 magId "2247263719" @default.
• W2247263719 workType "article" @default.